19.43

10.02% 1.74

Dyne Therapeutics Inc (DYN)

Overview News Price History Option Chain Financials Why DYN Down? Discussions Forecast

Dyne Therapeutics Inc stock is traded at $19.43, with a volume of 3.19M. It is up +10.02% in the last 24 hours and up +13.55% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Previous Close:

$17.69

Open:

$17.68

24h Volume:

3.19M

Relative Volume:

1.31

Market Cap:

$3.21B

Revenue:

Net Income/Loss:

$-412.89M

P/E Ratio:

-5.0337

EPS:

-3.86

Net Cash Flow:

$-361.93M

1W Performance:

+33.31%

1M Performance:

+13.55%

6M Performance:

+46.56%

1Y Performance:

+69.24%

1-Day Range:

$17.59

$20.03

1-Week Range:

$14.41

$20.03

52-Week Range:

$6.36

$25.00

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name

Dyne Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (618)

Phone

(781) 786-8230

Address

1560 TRAPELO ROAD, WALTHAM

Employee

206

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

DYN's Discussions on Twitter

Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DYN Dyne Therapeutics Inc	19.43	2.92B	0	-412.89M	-361.93M	-3.86
VRTX Vertex Pharmaceuticals Inc	496.55	117.08B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	779.08	82.63B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	743.34	45.82B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	322.37	42.92B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	307.12	33.54B	5.36B	287.73M	924.18M	2.5229

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy
Jun-24-25	Initiated	Bernstein	Mkt Perform
Jun-11-25	Resumed	Raymond James	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
May-29-25	Initiated	Evercore ISI	Outperform
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-13-24	Initiated	Robert W. Baird	Outperform
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral
May-21-24	Reiterated	Chardan Capital Markets	Buy
Apr-30-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	H.C. Wainwright	Buy
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy
Feb-15-23	Initiated	Oppenheimer	Outperform
Jan-26-23	Initiated	Guggenheim	Buy
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Outperform
Oct-12-20	Initiated	JP Morgan	Overweight
Oct-12-20	Initiated	Jefferies	Buy
Oct-12-20	Initiated	Piper Sandler	Overweight
Oct-12-20	Initiated	Stifel	Buy

View All

Dyne Therapeutics Inc Stock (DYN) Latest News

Mar 09, 2026

Dyne Therapeutics (DYN) Receives Analyst Rating Update from Char - GuruFocus

Mar 09, 2026

Baird reiterates Dyne Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada

Mar 09, 2026

Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN) - Seeking Alpha

Mar 09, 2026

Stifel reiterates Dyne Therapeutics stock rating on trial design By Investing.com - Investing.com Canada

Mar 09, 2026

Jones Trading reiterates Buy on Dyne Therapeutics stock after DMD, DM1 updates - Investing.com

Mar 09, 2026

Stifel reiterates Dyne Therapeutics stock rating on DMD data By Investing.com - Investing.com Canada

Mar 09, 2026

Stifel reiterates Dyne Therapeutics stock rating on DMD data - Investing.com

Mar 09, 2026

Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga

Mar 09, 2026

Rate Hike: Will Dyne Therapeutics Inc benefit from government policy2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn

Mar 09, 2026

Mar 08, 2026

Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria

Mar 08, 2026

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 - Investing News Network

Mar 08, 2026

Dyne Therapeutics (DYN) Begins Phase 3 Trial for Myotonic Dystro - GuruFocus

Mar 08, 2026

Dyne Therapeutics (DYN) Reveals Encouraging Results from Zelecim - GuruFocus

Mar 08, 2026

Dyne Therapeutics starts Phase 3 HARMONIA trial for z-basivarsen in DM1 - Traders Union

Mar 08, 2026

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - Bitget

Mar 08, 2026

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - Bitget

Mar 08, 2026

150-patient Dyne trial focuses on myotonic dystrophy daily function - Stock Titan

Mar 08, 2026

Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial Of Z-Rostudirsen In Duchenne Muscular Dystrophy (Dmd) - TradingView

Mar 08, 2026

Dyne DMD trial shows better breathing, heart health after 24 months - Stock Titan

Mar 08, 2026

Mar 06, 2026

A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical Progress - Yahoo Finance

Mar 06, 2026

Mar 05, 2026

Rafferty Asset Management LLC Boosts Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat

Mar 05, 2026

Mar 04, 2026

DYN: Validated platform and pipeline set stage for multiple rare disease launches and growth - TradingView

Mar 04, 2026